Trial · NCT01229254
Adverse events111
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 111
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Betrixaban 30 mg (+Amiodarone) | 2 | 42 | |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Betrixaban 60 mg (<80 kg) | 3 | 74 | |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Betrixaban 90 mg (≥80 kg) | 6 | 73 | |
| other | Upper respiratory tract infection | Infections and infestations | Betrixaban 30 mg (+Amiodarone) | 3 | 42 | |
| other | Upper respiratory tract infection | Infections and infestations | Betrixaban 60 mg (<80 kg) | 1 | 74 | |
| other | Upper respiratory tract infection | Infections and infestations | Betrixaban 90 mg (≥80 kg) | 6 | 73 | |
| other | Dizziness | Nervous system disorders | Betrixaban 30 mg (+Amiodarone) | 0 | 42 | |
| other | Dizziness | Nervous system disorders | Betrixaban 60 mg (<80 kg) | 9 | 74 | |
| other | Dizziness | Nervous system disorders | Betrixaban 90 mg (≥80 kg) | 5 | 73 | |
| other | Fatigue | General disorders | Betrixaban 30 mg (+Amiodarone) | 3 | 42 | |
| other | Fatigue | General disorders | Betrixaban 60 mg (<80 kg) | 5 | 74 | |
| other | Fatigue | General disorders | Betrixaban 90 mg (≥80 kg) | 5 | 73 | |
| other | Diarrhoea | Gastrointestinal disorders | Betrixaban 30 mg (+Amiodarone) | 2 | 42 | |
| other | Diarrhoea | Gastrointestinal disorders | Betrixaban 60 mg (<80 kg) | 4 | 74 | |
| other | Diarrhoea | Gastrointestinal disorders | Betrixaban 90 mg (≥80 kg) | 5 | 73 | |
| other | Oedema peripheral | General disorders | Betrixaban 30 mg (+Amiodarone) | 3 | 42 | |
| other | Oedema peripheral | General disorders | Betrixaban 60 mg (<80 kg) | 3 | 74 | |
| other | Oedema peripheral | General disorders | Betrixaban 90 mg (≥80 kg) | 5 | 73 | |
| other | Nausea | Gastrointestinal disorders | Betrixaban 30 mg (+Amiodarone) | 3 | 42 | |
| other | Nausea | Gastrointestinal disorders | Betrixaban 60 mg (<80 kg) | 2 | 74 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01229254/events